Oxford Biomedica, a gene and cell therapy company, and Homology Medicines, a genetic medicines company, formed Oxford Biomedica Solutions. Financial terms were not disclosed. “We are delighted to have closed this transaction. Oxford Biomedica is transforming into an innovative global viral vector leader that provides solutions to cell and gene therapy biotech and biopharma companies for their process development and manufacturing needs. Our ambition is to become a leading partner of choice with advanced capabilities across key vector types. This transaction also sees us form our first US operating subsidiary, located close to customers, talent, innovation in academia and pools of capital, which will enhance our market leadership position working across key viral vector types.Oxford Biomedica is in a strong position to enable our customers to bring their new medicines to many more patients and change their lives,” Roch Doliveux, Oxford Biomedica Chairman and CEO.